Access all of the content
It was a pleasure to be able to speak with John Stone (Massachusetts General Hospital, Boston, MA, USA) about the findings from his investigations into tocilizumab as a therapy for COVID-19 infection.
His presentation entitled ‘Tocilizumab for COVID-19 Infection: A Randomized, Double-Blind, Placebo-Controlled Trial’ (Abstract Number: L07) was presented at the ACR Convergence, 5-9 November.
- What is the rationale for the use of tocilizumab for COVID-19 infection? (0:16)
- What is the rationale for the use of tocilizumab for COVID-19 infection? (1:40)
- What might explain tocilizumab’s lack of efficacy in this treatment setting? (3:07)
- How do these findings compare with other studies of tocilizumab for COVID-19 infection? (4:32)
- Is tocilizumab likely to play any role in the treatment of COVID-19 outcomes? (5:20)
Disclosures: John H. Stone has received research funding from Roche, Principia, Viela Bio and Bristol Myers Squibb; and consulting fees from Roche, Principia, Viela Bio, Bristol Myers Squibb, Sanofi, Chemocentryx, Celgene, Abbvie, Chugai, Grunenthal, Glaxo Smith Kline, Infla Rx, Insmed, Regeneron, Roivant, Q32 bio, and SpruceBiosciences.
Support: Interview and filming supported by Touch Medical Media Ltd.
Filmed in coverage of virtual ACR Convergence 2020.
Share this Video
Related Videos In COVID-19
David Pesqué, EADV 2021: mRNA COVID-19 Vaccine Skin Reactions
It was an absolute pleasure to speak with Dr David Pesqué (Universitat Autònoma de Barcelona, Barcelona, Spain) about his study investigating the skin reactions seen in response to mRNA COVID-19 vaccines. His presentation entitled ‘Clinical characterization of skin reactions due to mRNA COVID-19 vaccines at a tertiary-level hospital: a descriptive study’ was given at the […]
Nancy Reau, DDW 2021: Hepatic Manifestations of COVID-19
It was a pleasure to speak with Prof. Nancy Reau (Rush Medical College, Chicago, IL, USA) about the hepatic manifestations of COVID-19 infection. Her presentation entitled ‘HEPATIC MANIFESTATIONS OF COVID-19: IS THERE CAUSE FOR CONCERN?’ was given at DDW, 21-23 May 2021 May 2021. Questions Could you give us a brief overview of the spectrum […]
Corey A Siegel: SARS-CoV-2 Vaccination for Patients with IBD
We were delighted to talk to Corey Siegel (Dartmouth-Hitchcock Medical Center, Lebanon, NH, US) around the IOIBD consensus statement on SARS-CoV-2 vaccination in patients with IBD. Questions What issues were discussed at the consensus meeting of the International Organization for the Study of Inflammatory Bowel Disease (IOIBD) regarding the safety and effectiveness of SARS-CoV-2 vaccination […]
Journal articles and more to your inbox
Get the latest clinical insights from touchIMMUNOLOGYSign me up!